Government of Ontario's Ministry of Health Approval of the Reimbursement of Rituxan (Rituximab) for the Treatment of Pemphigus

Government of Ontario's Ministry of Health Approval of the Reimbursement of 
Rituxan (Rituximab) for the Treatment of Pemphigus Vulgaris Announced 
TORONTO, Aug. 13, 2013 /CNW/ - The Canadian Pemphigus and Pemphigoid 
Foundation (CPPF) applauds the Government of Ontario's Ministry of Health and 
Long-Term Care decision to fund Rituxan (Rituximab) for the treatment of 
Pemphigus Vulgaris through the Ontario Public Drug Programs - Exceptional 
Access Program. Rituxan has improved the lives of many patients with 
pemphigus. CPPF is pleased to have been involved in a process that resulted in 
more patients with this challenging condition granted access to Rituxan. 
Pemphigus and pemphigoid are rare autoimmune diseases of the skin and/or 
mucous membranes that can be life threatening.In general, this spectrum of 
blistering diseases are very painful and even debilitating as patients need to 
wait weeks or months for standard therapies to take effect. The standard 
treatment options are not always effective and often have numerous, 
complicating side-effects. For pemphigus patients, and some pemphigoid 
patients, Rituxan is proving very effective. Blistering and rashes stopped 
spreading and patients were able to stop daily oral doses of steroids. 
"This is definitely a step in the right direction", said Dr. Neil Shear, Chair 
of the Canadian Pemphigus and Pemphigoid Foundation's Medical Advisory 
Council. "Rituxan, in our extensive experience, has been shown to be the 
safest, most effective and most economical treatment for immune blistering 
diseases. " 
The Foundation strongly encourages other provinces and territories to follow 
the Government of Ontario's lead. If successful, hundreds of patients will 
experience improved health outcomes. 
For more information on the Ontario Public Drug Program's Exceptional Access 
Program's reimbursement criteria visit 
http://www.health.gov.on.ca/en/pro/programs/drugs/eap_criteria.aspx (see pages 
38-39).
 

SOURCE  Canadian Pemphigus and Pemphigoid Foundation 
For more information on the Canadian Pemphigus and Pemphigoid Foundation  or 
to learn more about the disease, visitwww.pemphigus.ca and/or contact: 
Dr. Neil Shear Head of Dermatology, Sunnybrook Health Sciences Centre Chair - 
Canadian Pemphigus and Pemphigoid Foundation's Medical Advisory  Council 416 
480 4040 Public Relations Neil.Shear@sunnybrook.ca 
Leo Mieles Vice-Chair - Canadian Pemphigus and Pemphigoid Foundation's Board 
of  Directors leo.mieles@sympatico.ca or tel. 416 820 8156 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/August2013/13/c5581.html 
CO: Canadian Pemphigus and Pemphigoid Foundation
ST: Ontario
NI: HEA  
-0- Aug/13/2013 14:36 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.